Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEALING study of APAC in peripheral arterial occlusive disease and chronic limb-threatening ischemia
2025-522390-11-00Phase 2Authorised
- Sponsor
- Aplagon
- Start
- Jan 2026
- Countries
- 1
01
Overview
Phase 2, open-label trial of APAC in peripheral artery occlusion (PAD) and chronic limb-threatening ischemia (CLTI) (4 arms), sponsored by Aplagon. Primary endpoints: Safety and tolerability through D29/D90 and Safety and tolerability through D90. Planned start Jan 2026; status: authorised.
02
Drugs
APAC
03
Conditions
peripheral artery occlusion (PAD)chronic limb-threatening ischemia (CLTI)
Beyond the preview
Go deeper on 2025-522390-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522390-11-00.